Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks
LON:SBTX

SkinBioTherapeutics 3/26/2025 Earnings Report

SkinBioTherapeutics logo
GBX 14.25 0.00 (0.00%)
As of 10:40 AM Eastern
ProfileEarnings History

SkinBioTherapeutics EPS Results

Actual EPS
-GBX 0.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

SkinBioTherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SkinBioTherapeutics Announcement Details

Quarter
Date
3/26/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

SkinBioTherapeutics Earnings Headlines

SkinBioTherapeutics makes revenue gains on the back of recent acquisitions
August 14, 2025  |  msn.comhttps://www.msn.com/en-gb/health/other/skinbiotherapeutics-makes-revenue-gains-on-the-back-of-recent-acquisitions/ar-AA1KvdGt
SkinBioTherapeutics Raises £4.2 Million Through Share Issuance
June 20, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/skinbiotherapeutics-raises-4-2-million-through-share-issuance?utm_source=marketbeat.com&utm_medium=referral
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
August 29 at 2:00 AM  |  Paradigm Press (Ad)
SkinBioTherapeutics Appoints New Adviser and Broker
May 22, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/skinbiotherapeutics-appoints-new-adviser-and-broker?utm_source=marketbeat.com&utm_medium=referral
SkinBioTherapeutics Strengthens Leadership Amid Strategic Growth
April 24, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/skinbiotherapeutics-strengthens-leadership-amid-strategic-growth/ar-AA1DwpyP
SkinBioTherapeutics First Half 2025 Earnings: UK£0.005 loss per share (vs UK£0.008 loss in 1H 2024)
March 29, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/skinbiotherapeutics-first-half-2025-earnings-070048084.html
See More SkinBioTherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SkinBioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SkinBioTherapeutics and other key companies, straight to your email.

About SkinBioTherapeutics

SkinBioTherapeutics (LON:SBTX), a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

View SkinBioTherapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles